About Bexion Pharmaceuticals
Bexion Pharmaceuticals is a start-up company focused on the development of
cures for cancer. The Company has a first-in-class biologic product with
data-driven potential for treatment of a broad range of human cancers.
Specifically, the company is interested in first entering the clinic with a glioma
cancer indication, possibly simultaneously with a leukemia or pancreatic cancer
indication. The active biologic is expressed human Saposin C (SapC) bound to a
liposomal formulation of the anionic phospholipid, dioleoylphosphatidylserine
(DOPS) - SapC-DOPS.
Bexion Pharmaceuticals is a start-up company focused on the development of
cures for cancer. The Company has a first-in-class biologic product with
data-driven potential for treatment of a broad range of human cancers.
Specifically, the company is interested in first entering the clinic with a glioma
cancer indication, possibly simultaneously with a leukemia or pancreatic cancer
indication. The active biologic is expressed human Saposin C (SapC) bound to a
liposomal formulation of the anionic phospholipid, dioleoylphosphatidylserine
(DOPS) - SapC-DOPS.
Bexion has 3 strategic development interests:
1. Oncology therapeutics
2. Oncology diagnostics
3. Nucleic acid delivery
What We Do
We seek to commercialize innovative anti-cancer therapies. We begin with a
Platform Technology licensed from Cincinnati Children抯 Hospital: SapC-DOPS.
We seek to commercialize innovative anti-cancer therapies. We begin with a
Platform Technology licensed from Cincinnati Children抯 Hospital: SapC-DOPS.
To learn more about the tumor-targeting, apoptosis-inducing data and
mechanism of SapC-DOPS, start here.
mechanism of SapC-DOPS, start here.
